ERBB2 and breast cancer: HER2 represents a pivotal therapeutic target for precision medicine (19), is central to this association: clinical applications of HER2-directed agents (trastuzumab and pertuzumab) have been shown to significantly enhance pCR rates in HER2+ BC, thereby improving patient prognosis and quality of life.